Overall rank 26 · Score 106 · 2025 Oct
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
JACC. Heart failure
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 27 · Score 106 · 2025 Nov
Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
JACC. Heart failure
Randomized trialAI-recommended Tier ACardiovascularHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 28 · Score 106 · 2026 Oct
Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
Randomized trialAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 29 · Score 106 · 2026 Feb 1
Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.
JAMA psychiatry
Randomized trialAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 30 · Score 106 · 2026 Jan 22
Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.
BMC medicine
ObservationalAI-recommended Tier CReal-world evidence
AI appraisal complete: Prospective non-randomized comparative study; corrected from randomized trial. Evidence-class and Tier C recommendation updated from PubMed title/abstract, publication types, and registry metadata. No experimental retesting was performed or required.
Overall rank 31 · Score 106 · 2026 Mar
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
Nature medicine
Randomized trialAI-recommended Tier ASafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 32 · Score 106 · 2026 May 1
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
JAMA cardiology
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 33 · Score 106 · 2026 Jun
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 34 · Score 106 · 2026 Apr 22
LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
BMJ open
Other human/translationalAI-recommended Tier DMASH & liver
AI appraisal complete: Randomized-trial protocol without outcome results; corrected from completed randomized trial. Evidence-class and Tier D recommendation updated from PubMed title/abstract, publication types, and registry metadata. No experimental retesting was performed or required.
Overall rank 35 · Score 106 · 2026 May 2
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
Lancet (London, England)
Randomized trialAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 36 · Score 106 · 2026 Jul
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Nature medicine
Randomized trialAI-recommended Tier AWeight loss & obesity
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 37 · Score 106 · 2026 Aug
Multi-Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial.
Diabetes, obesity & metabolism
Randomized trialHeld · focused human exceptionKidney
AI appraisal complete; held from the publication bundle. Empagliflozin kidney MRI trial; Semaglutide is absent from the title and abstract.
Overall rank 38 · Score 106 · 2026 Jul 4
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 39 · Score 106 · 2026 Aug
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 40 · Score 106 · 2026 Sep 1
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.
The American journal of psychiatry
Randomized trialAI-recommended Tier AReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 41 · Score 106 · 2025 Feb
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 42 · Score 106 · 2025 May 3
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
Lancet (London, England)
Randomized trialAI-recommended Tier ASafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 43 · Score 106 · 2025 Jun 5
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
The New England journal of medicine
Randomized trialAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 44 · Score 106 · 2025 Dec 18
Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.
The Journal of clinical endocrinology and metabolism
Randomized trialAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 45 · Score 106 · 2025 Nov
Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.
American heart journal
Randomized trialAI-recommended Tier ACardiovascular
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 46 · Score 106 · 2025 Apr 30
Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4.
European journal of endocrinology
Randomized trialHeld · focused human exceptionPediatric & adolescent
AI appraisal complete; held from the publication bundle. Somapacitan pediatric growth-hormone trial; Semaglutide is absent from the title and abstract.
Overall rank 47 · Score 106 · 2025 Jul
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 48 · Score 106 · 2025 Jul
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 49 · Score 106 · 2025 May 28
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.
Journal of clinical medicine
Narrative reviewAI-recommended Tier DDiscontinuation & regain
AI appraisal complete: Narrative review of randomized studies; corrected from randomized trial. Evidence-class and Tier D recommendation updated from PubMed title/abstract, publication types, and registry metadata. No experimental retesting was performed or required.
Overall rank 50 · Score 106 · 2025 Sep 1
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.
Diabetes care
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.